About Caris life sciences
Caris Life Sciences: Revolutionizing Precision Oncology
Cancer is a complex disease that affects millions of people worldwide. It is a leading cause of death, and the search for effective treatments has been ongoing for decades. In recent years, precision oncology has emerged as a promising approach to cancer treatment. This approach involves analyzing the genetic makeup of tumors to identify specific mutations that drive cancer growth. By targeting these mutations with personalized therapies, precision oncology aims to improve patient outcomes and reduce side effects.
Caris Life Sciences is at the forefront of precision oncology research and development. Founded in 2008, Caris has quickly become a leader in advanced laboratory testing for cancer patients. The company's mission is to fulfill the promise of precision oncology by providing accurate and reliable tumor profiling and blood-based cancer diagnostics.
Tumor Profiling: A Game-Changer in Cancer Treatment
Tumor profiling is an essential component of precision oncology. It involves analyzing the genetic makeup of tumors to identify specific mutations that are driving cancer growth. By identifying these mutations, doctors can develop personalized treatment plans tailored to each patient's unique needs.
Caris offers comprehensive tumor profiling services using state-of-the-art technology such as next-generation sequencing (NGS) and immunohistochemistry (IHC). These tests provide detailed information about the genetic alterations present in a patient's tumor, including DNA mutations, gene fusions, copy number variations (CNVs), and protein expression levels.
The results from Caris' tumor profiling tests are used by physicians to guide treatment decisions for their patients. For example, if a patient's tumor has a mutation in a particular gene that drives cancer growth, their doctor may recommend targeted therapy with drugs that specifically inhibit that gene's activity.
Blood-Based Cancer Diagnostics: A Non-Invasive Alternative
In addition to tumor profiling, Caris also offers blood-based cancer diagnostics using its proprietary ADAPT Biotargeting System™ technology platform. This innovative approach allows doctors to detect circulating tumor DNA (ctDNA) in patients' blood samples without invasive biopsies or surgeries.
The ADAPT platform uses highly sensitive assays capable of detecting ctDNA at very low concentrations in patients' blood samples. This technology enables early detection of cancers before they become symptomatic or visible on imaging scans such as CT or MRI scans.
Blood-based testing also provides valuable information about how tumors are responding to treatment over time by monitoring changes in ctDNA levels during therapy courses.
Clinical Trials: Advancing Precision Oncology Research
Caris is committed not only to providing cutting-edge diagnostic services but also advancing research into new treatments for cancers through clinical trials participation across multiple therapeutic areas including breast cancer trials , lung trials , pancreatic trials , prostate trials etc . The company collaborates with leading academic institutions and pharmaceutical companies worldwide on clinical studies aimed at developing new therapies based on genomic insights into individual cancers .
By participating actively in clinical research programs across various therapeutic areas like breast , lung , pancreatic etc., Caris helps accelerate progress towards more effective treatments for all types of cancers .
Conclusion:
Precision oncology represents an exciting new frontier in cancer treatment . With its advanced laboratory testing capabilities like Tumor Profiling & Blood-Based Cancer Diagnostics along with active participation across multiple therapeutic areas through Clinical Trials - Caris Life Sciences plays an important role revolutionizing this field . Through its commitment towards innovation & collaboration with leading academic institutions & pharmaceutical companies worldwide - it continues making significant contributions towards improving outcomes for all those affected by this devastating disease .